SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
YARW

Yarrow Bioscience, Inc. (YARW)

NASDAQ: YARW · Real-Time Price · USD
Healthcare · Biotechnology
$13.93-$4.10 (-22.74%)
 
Market cap
$160M
Insider Score
Analyst consensus
Market Cap$159.82M-25.5%
Revenue (ttm)n/a
Net Income-$283.98M
EPSn/a
Shares Out11.47M
PE Ration/a
Forward PE-8.44
Dividendn/a
Ex-Dividend DateJul 24, 2026
Volume264,641
Open$18.03
Previous Close$18.03
Day's Range$13.75 - $19.35
52-Week Range$12.38 - $46.95
Beta2.13
AnalystsStrong Buy
Price Target$57.33(+311.58%)
Earnings Daten/a
-22.74% (1D)
No price history available.

About YARW

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Address
40 10 th Avenue, New York, NY, 10014, United States
Market Cap
160 million
Employees
7
Industrial Classification
Biotechnology
1 Day
-22.74%
5 Days
-11.78%
1 Month
-23.92%
6 Months
-58.79%
1 Year
-25.51%

$YARW stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in YARW holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by YARW's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

YARW Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New YARW patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to YARW from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from YARW’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
72

News check: Yarrow successfully completed a $172.5M public offering with full underwriter option exercise, demonstrating strong investor demand and capital raising execution.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.